First Time Loading...
R

Rekah Pharmaceutical Industry Ltd
TASE:REKA

Watchlist Manager
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Watchlist
Price: 1 356 ILS 0.89% Market Closed
Updated: May 10, 2024

Intrinsic Value

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. [ Read More ]

The intrinsic value of one REKA stock under the Base Case scenario is 1 983.2 ILS. Compared to the current market price of 1 356 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 32%.

Key Points:
REKA Intrinsic Value
Base Case
1 983.2 ILS
Undervaluation 32%
Intrinsic Value
Price
R
Worst Case
Base Case
Best Case

Valuation Backtest
Rekah Pharmaceutical Industry Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling REKA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Rekah Pharmaceutical Industry Ltd

Provide an overview of the primary business activities
of Rekah Pharmaceutical Industry Ltd.

What unique competitive advantages
does Rekah Pharmaceutical Industry Ltd hold over its rivals?

What risks and challenges
does Rekah Pharmaceutical Industry Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Rekah Pharmaceutical Industry Ltd.

Provide P/S
for Rekah Pharmaceutical Industry Ltd.

Provide P/E
for Rekah Pharmaceutical Industry Ltd.

Provide P/OCF
for Rekah Pharmaceutical Industry Ltd.

Provide P/FCFE
for Rekah Pharmaceutical Industry Ltd.

Provide P/B
for Rekah Pharmaceutical Industry Ltd.

Provide EV/S
for Rekah Pharmaceutical Industry Ltd.

Provide EV/GP
for Rekah Pharmaceutical Industry Ltd.

Provide EV/EBITDA
for Rekah Pharmaceutical Industry Ltd.

Provide EV/EBIT
for Rekah Pharmaceutical Industry Ltd.

Provide EV/OCF
for Rekah Pharmaceutical Industry Ltd.

Provide EV/FCFF
for Rekah Pharmaceutical Industry Ltd.

Provide EV/IC
for Rekah Pharmaceutical Industry Ltd.

Compare the intrinsic valuations
of Rekah Pharmaceutical Industry Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Rekah Pharmaceutical Industry Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Rekah Pharmaceutical Industry Ltd compared to its peers.

Compare the P/E ratios
of Rekah Pharmaceutical Industry Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Rekah Pharmaceutical Industry Ltd with its peers.

Analyze the financial leverage
of Rekah Pharmaceutical Industry Ltd compared to its main competitors.

Show all profitability ratios
for Rekah Pharmaceutical Industry Ltd.

Provide ROE
for Rekah Pharmaceutical Industry Ltd.

Provide ROA
for Rekah Pharmaceutical Industry Ltd.

Provide ROIC
for Rekah Pharmaceutical Industry Ltd.

Provide ROCE
for Rekah Pharmaceutical Industry Ltd.

Provide Gross Margin
for Rekah Pharmaceutical Industry Ltd.

Provide Operating Margin
for Rekah Pharmaceutical Industry Ltd.

Provide Net Margin
for Rekah Pharmaceutical Industry Ltd.

Provide FCF Margin
for Rekah Pharmaceutical Industry Ltd.

Show all solvency ratios
for Rekah Pharmaceutical Industry Ltd.

Provide D/E Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide D/A Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Interest Coverage Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Altman Z-Score Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Quick Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Current Ratio
for Rekah Pharmaceutical Industry Ltd.

Provide Cash Ratio
for Rekah Pharmaceutical Industry Ltd.

What is the historical Revenue growth
over the last 5 years for Rekah Pharmaceutical Industry Ltd?

What is the historical Net Income growth
over the last 5 years for Rekah Pharmaceutical Industry Ltd?

What is the current Free Cash Flow
of Rekah Pharmaceutical Industry Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Rekah Pharmaceutical Industry Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Rekah Pharmaceutical Industry Ltd

Current Assets 237.3m
Cash & Short-Term Investments 14m
Receivables 126.1m
Other Current Assets 97.1m
Non-Current Assets 233.7m
Long-Term Investments 1.3m
PP&E 153.7m
Intangibles 66m
Other Non-Current Assets 12.7m
Current Liabilities 140.9m
Accounts Payable 93m
Short-Term Debt 24.2m
Other Current Liabilities 23.7m
Non-Current Liabilities 173.7m
Long-Term Debt 138.5m
Other Non-Current Liabilities 35.2m
Efficiency

Earnings Waterfall
Rekah Pharmaceutical Industry Ltd

Revenue
315.3m ILS
Cost of Revenue
-235.6m ILS
Gross Profit
79.7m ILS
Operating Expenses
-74.1m ILS
Operating Income
5.6m ILS
Other Expenses
-14m ILS
Net Income
-8.4m ILS

Free Cash Flow Analysis
Rekah Pharmaceutical Industry Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

REKA Profitability Score
Profitability Due Diligence

Rekah Pharmaceutical Industry Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive Free Cash Flow
Positive 1-Year Revenue Growth
43/100
Profitability
Score

Rekah Pharmaceutical Industry Ltd's profitability score is 43/100. The higher the profitability score, the more profitable the company is.

REKA Solvency Score
Solvency Due Diligence

Rekah Pharmaceutical Industry Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Average D/E
Low Altman Z-Score
31/100
Solvency
Score

Rekah Pharmaceutical Industry Ltd's solvency score is 31/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

REKA Price Targets Summary
Rekah Pharmaceutical Industry Ltd

There are no price targets for REKA.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

REKA Price
Rekah Pharmaceutical Industry Ltd

1M 1M
-3%
6M 6M
-2%
1Y 1Y
-13%
3Y 3Y
-40%
5Y 5Y
-45%
10Y 10Y
+5%
Annual Price Range
1 356
52w Low
1 270
52w High
1 838
Price Metrics
Average Annual Return -7.84%
Standard Deviation of Annual Returns 28.76%
Max Drawdown -55%
Shares Statistics
Market Capitalization 160.5m ILS
Shares Outstanding 118 385
Percentage of Shares Shorted
N/A

REKA Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Rekah Pharmaceutical Industry Ltd

Country

Israel

Industry

Pharmaceuticals

Market Cap

160.5m ILS

Dividend Yield

0%

Description

Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.

Contact

Holon
30 Hamelach Street, Ezor Hata`Asiya, T.D. 25
+97235581233
https://www.rekah.co.il/

IPO

1995-12-14

Employees

399

Officers

CEO & Director
Mr. Mordechai Elgrabli
Chief Financial Officer
Mr. Yuval Bernshtein CPA
Director of Industrial Division & Director
Ms. Georgette Elgrabli
Chief Executive Officer of Ophir Shalpharm
Mr. Jacob Elgrably
Director of Operations
Mr. Meir Melumad
Deputy CEO & Director of Business Development
Mr. Yuval Elgrabli
Show More
Chief Executive Officer of Ophir & Shalpharm Ltd
Mr. Yaakov Elgrabli
Chief Executive Officer - Fresh of Life Pharma Ltd.
Mr. Nir Sella
Show Less

See Also

Discover More
What is the Intrinsic Value of one REKA stock?

The intrinsic value of one REKA stock under the Base Case scenario is 1 983.2 ILS.

Is REKA stock undervalued or overvalued?

Compared to the current market price of 1 356 ILS, Rekah Pharmaceutical Industry Ltd is Undervalued by 32%.